the aid library

Following the Money. Lack of Transparency in Donor Funding for Syrian Refugee Education

Human Rights Watch (2017) C1

High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova

H. E. Jenkins, V. Crudu, V. Soltan, et al. National Institute of Health (2014) C2

Eur Respir J. 2014 April ; 43(4): 1132–1141. doi:10.1183/09031936.00203613.

The ASSIST-linked brief intervention for hazardous and harmful substance use

World Health Organization WHO (2010) C_WHO

Manual for use in primary care. This manual explains the theoretical basis and evidence for the effectiveness of brief interventions and assists primary health care workers in conducting a simple brief intervention for clients whose substance use is putting them at risk.

Excess mortality during the Coronavirus pandemic (COVID-19)
recommended

Giattino, C.; H. Ritchie, M. Roser, et al. One World Data (2021) CC

On this page we provide an overview of excess mortality along with charts to explore the data. You can learn in more depth about different measures of excess mortality, their strengths and limitations, and their comparability across countries

Chance Ebola Can Be Defeated by End of 2015

World Health Organization (2015)

World Health Organization Chief Tells Security Council, Urging Sustained Focus to Prevent Future Outbreaks

Health at a Glance: Latin America and the Caribbean 2020

OECD; The World Bank (2020) C1

Thefirst report on Latin America and the Carribean presents key indicators on health and health systems in 33 Latin America and the Caribbean countries. . Analysis is based on the latest comparable data across almost 100 indicators including equity, health status, determinants of health, health car ... more

Clinic-based survey of acquired HIV drug residence

World Health Organization WHO (2021) C_WHO

WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens. Results are used to inform A ... more

Addressing gender inequalities in national action plans on antimicrobial resistance

World Health Organisation (WHO) (2024) C_WHO

National action plans on antimicrobial resistance (AMR) often overlook the critical intersection of gender, despite evidence that exposure and susceptibility to infection, health-seeking behaviours, as well as antimicrobial prescribing and use patterns are all influenced by gender.

Cameroon: Identifying Challenges in the Disability Community in Bamenda and its Surrounding Areas

Rachel Chaikof (2015) CC

Medicine Prices in Nigeria

Federal Ministry of Health Nigeria , World Health Organisation (WHO), DFID, et al. (2006) C_WHO

Prices people pay for medicines.

Disability-inclusive social protection research in Vietnam

Banks, Lena M., Walsham, Matthew and others International Centre for Evidence in Disability (2018) C1

A national overview with a case study from Cam Le district
The overall aims of this study are (1) to assess the extent to which social protection systems in Vietnam address the needs of people with disabilities; and (2) to identify and document elements of good practice, as well as challenges, ... more

Assessment of the Pharmaceutical situation in Kenya: A Baseline Survey.

World Health Organization WHO; HAI (2003) C_WHO

Inclusive Education for Children with Disabilities

CRSVietnam Education Team Catholic Relief Services (CRS) (2007) C2

How-to Guide Series

Levels and Determinants of Use of Institutional Delivery Care Services among Women of Childbearing Age in Ethiopia: Analysis of EDHS 2000 and 2005 Data.

Mehari, Asmeret Moges ICF International (2013) C2

DHS Working Papers No. 83.

Factors influencing ART adherence: Qualitative findings from selected sites in Tanzania - January 2008

Ministry of Health and Social Welfare, Tanzania (2008) C1

At any price?

BUKO Pharma-Kampagne (2011) C1

Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India